Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
Aug 17, 2018•3 min
Episode description
Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic prostate cancer, asking whether it could find a place as treatment for a subset of these patients.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast